Share

Blue-blooded

We’re in the age of innovation yet our economy, medical industry and way of life rest on the shell of a crustacean older than the dinosaurs.

The 450 million-year-old horseshoe crab plays an integral role in Covid vaccine production and most medical innovation so far.

It sounds like deep science fiction, but the blue blood of horseshoe crabs is harvested by the healthcare industry. Each litre comes in at US$16,000. Google the topic for some horrifying images.

Their blood is the only known producer of limulus amebocyte lysate. These cells can detect a bacteria called endotoxin. Any amount of endotoxin in the body can prove deadly. The blood is used to test for its presence on needles, pharmaceuticals and prosthetics. Each year, 400,000 crabs are bled.

Of course, this isn’t a perfectly sustainable or harmless action. Crab numbers in some parts of America have fallen by 60% since 1990. It is estimated that 30% of crabs die during the process, even if they are returned to the ocean after bleeding. Where’s the artificial alternative? It’s coming but humans are struggling to outpace hundreds of millions of years of natural development. In 2016, a synthetic variation was discovered with moderate adoption but by 2020, US regulators refused to declare the alternative as effective.

The medical community is aware of our reliance on such a fragile and scarce resource. Natural disasters, oil spills, global warming all affect the crab populations and indirectly our ability to produce life-saving medicines.  It may sound sensationalised but the race for a safe synthetic solution is on. 


Want more?

You know what to do

Insights, trends and company deep dives delivered straight to your inbox.


Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd is registered as an overseas company in New Zealand (NZBN: 9429047452152), and is registered as a Financial Service Provider under the Financial Service Providers (Registration and Dispute Resolution) Act 2008 (No. FSP774414). We hold a full licence issued by the Financial Markets Authority to provide a financial advice service under the Financial Markets Conduct Act 2013. However, the content on this website has not been prepared to take into account any of your individual objectives, financial situation or needs. To the extent you require further information about the relevant New Zealand legislation that may apply, or require specific advice, please contact your legal and/or financial adviser (as appropriate). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Terms & Conditions, Privacy Policy, Financial Advice Disclosure and Disclaimers before deciding to use or invest on Stake. By using the Stake website or service in any way, you agree to our Privacy Policy and Terms & Conditions All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake is a registered trademark under class 36 (New Zealand).

Copyright © 2024 Stake. All rights reserved.